One of the key findings in recent studies is the role of glucagon-like peptide-1 (GLP-1) in postprandial hypoglycemia. After bariatric surgery, the body often experiences an exaggerated release of ...

Bariatric surgery is currently the most ... treatment of diabetes and obesity is currently limited. The glucagon-like peptide-1 receptor agonists improve glycemia and induce a modest weight ...

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

To qualify for hip replacement surgery, she needed to lose 100 ... But then Golden turned to glucagon-like peptide 1 (GLP-1) receptor agonists, and they delivered. Leslie Golden, MD, MPH, DABM ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.